L'Edoxaban (lixiana®): Propriétés et atouts d'un nouvel anticoagulant oral pour le traitement de la maladie thombo-embolique veineuse

Venous thromboembolism (VTE) is a public health challenge and a major cause of morbidity and mortalily. The Hokusai-VTE study is a randomized double-blind study that evaluated whether heparin (5 days) followed by an oral factor Xa inhibitor, Edoxaban, at a dose of 60 mg/day is an alternative to conventional treatment (heparin (5 days) followed by warfarin (target INR between 2 and 3)) for the prevention of recurrence in patients with acute VTE. This study demonstrated in patients with VTE, Including a large subgroup with severe pulmonary embolism and right ventricular dysfunction, non-inferiority of heparin therapy (5 days) followed by Edoxaban 60 mg/day compared to standard treatment. In terms of safely, less bleeding episodes were recorded in the Heparin-Edoxaban, at least for fatal and intracranial bleedings while there was no statistically significant difference for major bleeding complications. Half-dose of Edoxaban (30 mg/day) in patients at increased risk of bleeding (renal failure, low body-weight, co-medlcation with agents that inhibit P-glycoproteln which is a substrate Edoxaban) proved to be safe and effective.